Breeze Holdings Acquisition Corp. shareholders approved the business combination with YD Biopharma Limited.
The transaction is expected to close within the next two weeks, subject to customary closing conditions.
Upon closing, the combined company will operate as YD Bio Limited and trade on Nasdaq under the ticker symbol 'YDES'.
Business Combination Approval
Shareholders voted in favor of the Business Combination with an overwhelming majority of 3,127,474 shares in favor.
Stockholder Meeting Quorum
A quorum was established with 3,128,495 shares represented in person or by proxy.
Advisors
ArentFox Schiff LLP is the legal advisor to YD Biopharma, while I-Bankers Securities, Inc. is the financial advisor to Breeze.
- The combined company will focus on cancer prevention medical diagnostics and developing exosome-based therapeutics.
- YD Biopharma is positioned to transform the treatment of diseases with high unmet medical needs through innovation.
- The transaction signifies a strategic move towards expanding YD Biopharma's market presence and offerings.
The approval of the business combination marks a significant step for Breeze Holdings Acquisition Corp. and YD Biopharma Limited, setting the stage for growth and market expansion.